Research programme: influenza monoclonal antibody therapeutics - ContraFect/Trellis

Drug Profile

Research programme: influenza monoclonal antibody therapeutics - ContraFect/Trellis

Alternative Names: Anti-H1 mAb - ContraFect; Anti-H3 mAb - ContraFect; Anti-Influenza mAb combination - ContraFect; CF 401; CF 402; CF 403; CF 404

Latest Information Update: 17 May 2016

Price : $50

At a glance

  • Originator Trellis Bioscience
  • Developer ContraFect; Trellis Bioscience
  • Class Monoclonal antibodies
  • Mechanism of Action Influenza virus haemagglutinin glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Influenza A virus infections; Influenza B virus infections

Most Recent Events

  • 10 May 2016 ContraFect announces intention to submit IND in second mid of 2017
  • 05 Feb 2015 Update on CF-401 to now be presented in Feb 2015
  • 09 Oct 2014 ContraFect and the National Institute of Viral Disease Control and Prevention in China agree to collaborate on development of CF 404
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top